Menu
ADL Condemns' 'Absurd' U.N. Special Session on Jerusalem

ADL Condemns' 'Absurd' U.N. Special…

New York, NY, The Anti-De...

Jerusalem is our capital. We will continue to build in it and foreign embassies, led by the US embassy, will move to Jerusalem. It will happen.​

Jerusalem is our capital. We will c…

PM Netanyahu's remarks at...

ADL Monitoring Anti-Israel Rallies Globally: Anti-Semitic Images Appear in Arabic Language Media Following Trump Action on Jerusalem

ADL Monitoring Anti-Israel Rallies …

New York, NY,  Anti-...

PM Netanyahu attends MFA Chanukah candle-lighting ceremony

PM Netanyahu attends MFA Chanukah c…

​A great light emanates f...

Facebook, Google, Microsoft, Twitter, and ADL Announce Lab to Engineer New Solutions to Stop Cyberhate

Facebook, Google, Microsoft, Twitte…

New York, NY -  Face...

ADL to Challenge Justice Department Religious Liberty Guidance Calls it a “Roadmap for Discrimination”

ADL to Challenge Justice Department…

New York, NY- - The Anti-...

JWV Welcomes Greater Accountability for VA Employees

JWV Welcomes Greater Accountability…

The Department of Veteran...

Alice and Nahum Lainer Family Foundation Donates Transformative Endowment Gift to Sinai Akiba Academy

Alice and Nahum Lainer Family Found…

Los Angeles, California -...

Swiss Town Returns Painting Looted during World War II

Swiss Town Returns Painting Looted …

Following a lengthy legal...

PM Netanyahu welcomes US President Trump’s decision regarding Iran

PM Netanyahu welcomes US President …

​PM Netanyahu: President ...

Prev Next
A+ A A-

Teva Announces: President and CEO. Dr. Jeremy Levin steps down as President and CEO, Eyal Desheh, Teva's Group EVP & Chief Financial Officer, named interim President and CEO Featured

JERUSALEM, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that its Board of Directors has agreed with Dr. Jeremy Levin that he will step down as President and Chief Executive Officer. The Board has named Eyal Desheh, Teva's Executive Vice President and Chief Financial Officer, to fill the role of President and Chief Executive Officer on an interim basis, effective immediately, and it has formed a committee that will promptly begin to search for a permanent successor. 

Dr. Phillip Frost, Chairman of the Board, stated “On behalf of the entire Board of Directors, I would like to thank Dr. Jeremy Levin for his meaningful contribution to Teva during the last two years. The Board and management team are fully committed to the implementation of Teva's strategy, including the development of new compounds, making strategic acquisitions, forming joint ventures and the planned acceleration of the Company’s cost reduction program.”

“Since I joined Teva, we have made tremendous progress in setting a new course for the Company,” said Dr. Jeremy Levin. "I wish the Company and its people, who I respect greatly, every success. I look forward to pursuing new opportunities where I can continue to apply my experience and contribute to the evolution of the global pharmaceutical industry.”

"I have full confidence in the ability of Teva's management and employees to achieve our goals and execute the strategy laid out for the Company,” said Eyal Desheh, who has served at Teva for over 12 years, including the last five as Chief Financial Officer. “My colleagues in Teva's management and I will continue to drive execution and results in full collaboration with our Board of Directors, for the benefit of our patients, shareholders, customers and employees."

As previously scheduled, Teva will report its third quarter 2013 financial results on October 31, 2013.
Last modified onMonday, 09 January 2017 15:10

Leave a comment

Make sure you enter the (*) required information where indicated. HTML code is not allowed.

back to top

Sections

Jewish Traditions

About Us

Community

Cooperations

Follow Us